Chemotherapy in metastatic non-small-cell lung cancer

ONCOLOGY

Volumn 14, Issue 7 SUPPL. 5, 2000, Pages 15-27

  Sandler, Alan ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DOCETAXEL; DRUG DERIVATIVE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; TAXOID; TIRAPAZAMINE; TRIAZINE DERIVATIVE; VINBLASTINE;

CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; PATHOLOGY; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS; DEOXYCYTIDINE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MITOMYCIN; PACLITAXEL; TAXOIDS; TRIAZINES; VINBLASTINE;

EID: 0034220252     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Friese G, Gabler A, Liebig S: Bronchial carcinoma and long-term survival. Thorax 33:228-234, 1978.
2. Greenlee R, Murray T, Bolden S, et al: Cancer Statistics 2000. CA Cancer J Clin 50:7-33, 2000.
3. Vogl SE, Berenzweig M, Camacho F, et al: Efficacy study of intensive cisplatin therapy in advanced non-small-cell bronchogenic carcinoma. Cancer 50:24-26, 1982.
4. Schabel FM Jr, Trader MW, Laster WR Jr, et al: Cis-dichlorodiammineplatinum(II): Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459-1473, 1979.
5. Parker RJ, Dabholkar MD, Lee KB, et al: Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr 15:83-88, 1993.
6. Jekunen AP, Christen RD, Shalinsky DR, et al: Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69:299-306, 1994.
7. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991.
8. LeBlanc GA, Sundseth SS, Weber GF, et al: Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 52:540-547, 1992.
9. Klastersky J, Sculier JP: Cisplatin plus taxol in non-small-cell lung cancer: A dose finding trial. Proc Am Assoc Cancer Res 36:1423, 1995.
10. Belli L, LeChevalier T, Gottfried M, et al: Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer: Preliminary results. Semin Oncol 22(suppl 15):29-33, 1995.
11. Rowinsky EK, Chaudhry V, Forastiere AA, et al: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010-2020, 1993.
12. Pirker R, Krajnik G, Zochbauer S, et al: Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 6:833-835, 1995.